일본 보건 당국이 스미토모 파마의 iPS 세포 유래 파킨슨병 치료제인 '암체프리(Amchepry)'에 대한 국민건강보험 적용을 승인했다. 이로써 해당 제품은 세계 최초로 상용화된 iPS 세포 치료제가 됐다.
이번 승인은 일본 후생노동성 산하 전문위원회를 통해 결정되었으며, 스미토모 파마의 파킨슨병 치료제 암체프리에 대한 보험 적용을 확정했다.
암체프리는 유도만능줄기세포(iPS 세포)를 이용해 제조된 치료제로, 이번 결정으로 인해 세계 최초로 상용화된 iPS 세포 유래 치료제라는 지위를 확보하게 되었다.
해당 위원회의 조치로 일본의 국민건강보험 체계를 통해 더 많은 환자들이 치료제를 이용할 수 있는 길이 열리게 되었다.
AI에 의해 보고됨 AI에 의해 생성된 이미지
A health ministry expert panel has conditionally approved two regenerative medicine products derived from induced pluripotent stem (iPS) cells for treating Parkinson's disease and severe heart disease. This marks a potential world first in commercializing Nobel Prize-winning stem cell technology. The approval, based on small-scale clinical trials confirming safety and presumed efficacy, requires post-market verification within seven years.
Following an expert panel's recommendation last month, Japan's Health, Labor and Welfare Ministry on March 6 conditionally approved two iPS cell-derived regenerative medicines—the world's first commercialized such treatments—for severe heart failure and Parkinson's disease. The products carry conditions and time limits, with pricing and insurance coverage decisions next; sales could begin as early as summer 2026.
AI에 의해 보고됨
Japan's health ministry panel on Thursday approved the commercialization of two regenerative medicine products derived from iPS cells, marking a global first. These treatments target patients with severe heart failure and Parkinson's disease, under a conditional approval requiring data collection for up to seven years. Shinya Yamanaka, pioneer of iPS cell research, expressed delight at this milestone.
Sequencio, a new Hong Kong unit of CK Life Sciences, is advancing about 20 cancer vaccine projects via China's faster pathway to human trials. CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh Kean-meng said the firm plans investigator-initiated trials next year.
AI에 의해 보고됨
PhilHealth has expanded its Z Benefits Package to cover at least 10 rare genetic conditions. The benefits include case rates ranging from roughly P99,000 to P739,000. This move supports ongoing efforts to improve care for rare disease patients in the Philippines.